Argos Therapeutics, Inc. (NASDAQ:ARGS) shares traded up 12.6% during mid-day trading on Wednesday . The company traded as high as $0.25 and last traded at $0.23. 8,719,080 shares were traded during trading, an increase of 365% from the average session volume of 1,873,760 shares. The stock had previously closed at $0.20.

Separately, Zacks Investment Research cut Argos Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $3.23.

The company’s market capitalization is $11.38 million. The stock’s 50-day moving average price is $0.24 and its 200 day moving average price is $0.52.

Argos Therapeutics (NASDAQ:ARGS) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. The business had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.10 million. Argos Therapeutics had a negative return on equity of 1,532.49% and a negative net margin of 12,391.15%. On average, equities analysts forecast that Argos Therapeutics, Inc. will post ($1.14) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.